Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05533372 · ClinicalTrials.gov registry record · Phase 1
MAD Study of IA-14069
A Phase 1 study of Healthy and Rheumatoid Arthritis, sponsored by ILAb Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT05533372: Recruiting Phase 1 study of Healthy and Rheumatoid Arthritis, sponsored by ILAb Co..
NCT05533372 is a Phase 1 study of Healthy and Rheumatoid Arthritis that is actively recruiting participants, run by ILAb Co.. The registered enrollment target is 75 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05533372, a Phase 1 study of Healthy and Rheumatoid Arthritis, is actively recruiting participants, sponsored by ILAb Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of IA-14069 in healthy subjects and in patients with RA on stable dosese of MTX, with preliminary assessment of efficacy in RA patients.
Primary Outcome
Incidence and severity of adverse events (AEs) and serious AEs, including clinical laboratory values, vital signs, 12-lead electrocardiograms, and physical examination; changes from baseline.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Methotrexate
- DRUG IA-14069
Study Locations (1)
Kansas
- ICON plc. - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-10-10 |
| Est. Completion | 2026-02 |
| Phase | Phase 1 |
What NCT05533372 shows while recruiting
NCT05533372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05533372 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT05533372 about?
NCT05533372 is a clinical study titled "MAD Study of IA-14069". The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of IA-14069 in healthy subjects and in patients with RA on stable dosese of MTX, with preliminary assessment of efficacy in RA patients.
What is the current status of trial NCT05533372?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2022-10-10. Estimated completion is 2026-02.
What conditions does trial NCT05533372 study?
This clinical trial studies the following conditions: Healthy, Rheumatoid Arthritis.
What interventions are being tested in trial NCT05533372?
The interventions under investigation include: Placebo (DRUG), Methotrexate (DRUG), IA-14069 (DRUG).
Who is sponsoring clinical trial NCT05533372?
This trial is sponsored by ILAb Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05533372 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05533372's enrollment target sits among peer trials
75 300th of 1090 higher than 781 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI